Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Monika Dlugosz-Danecka"'
Autor:
Max Topp, Monika Dlugosz-Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot, Andreas K. Klein, Georg Hess, Christian S. Michel, Sebastian Grosicki, Alex Gural, Sylvia E. Schwarz, Kerstin Pietzko, Ulrike Gärtner, András Strassz, Leila Alland, Jiri Mayer
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treat
Externí odkaz:
https://doaj.org/article/733ebcc0ead14adca31fae5c33809819
Autor:
Andrew M. Evens, Joseph M. Connors, Anas Younes, Stephen M. Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J. Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Dlugosz-Danecka, Keenan Fenton, Andres Forero-Torres, Rachael Liu, Hina Jolin, Ashish Gautam, Andrea Gallamini
Publikováno v:
Haematologica, Vol 107, Iss 5 (2021)
Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma. We report results for older patients with classical Hodgkin lymphoma treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plu
Externí odkaz:
https://doaj.org/article/05ad3efbc3ef4677a99a0a0fd38b3d53
Autor:
Max Topp, Monika Dlugosz-Danecka, Aleksander B. Skotnicki, Galina Salogub, Andreas Viardot, Andreas K. Klein, Georg Hess, Christian S. Michel, Sebastian Grosicki, Alex Gural, Sylvia E. Schwarz, Kerstin Pietzko, Ulrike Gärtner, András Strassz, Leila Alland, Jiri Mayer
Background The prognosis for patients with relapsed and/or refractory (R/R) non-Hodgkin’s lymphoma (NHL) or acute lymphoblastic leukaemia (ALL) remains poor, with existing treatments having significant side effects. Developed for the treatment of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c0e89131dea4b976b7f85b86b2d5471
https://doi.org/10.21203/rs.3.rs-1113841/v1
https://doi.org/10.21203/rs.3.rs-1113841/v1
Autor:
Edward T.H. Yeh, Michael S. Ewer, Javid Moslehi, Monika Dlugosz-Danecka, Jose Banchs, Hui-Ming Chang, Giorgio Minotti
Publikováno v:
Seminars in Oncology. 46:397-402
The opening session of Second International Colloquium on Cardio-Oncology addressed two areas of vital interest. The first reviewed new thoughts related to established agents. While anthracycline cardiotoxicity has been studied and reviewed extensive
Autor:
David J. Straus, Monika Dlugosz-Danecka, Joseph M. Connors, Árpád Illés, Marco Picardi, Ewa Lech-Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Munoz, Won Seog Kim, Ranjana Advani, Stephen M. Ansell, Anas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle A. Fanale, John A. Radford
Publikováno v:
Blood. 136:26-28
Introduction Historically, nearly all relapses in classical Hodgkin lymphoma (cHL) occur within the first 5 years (Radford et al, BMJ 1997). In the phase 3 ECHELON-1 study (NCT01712490), treatment with brentuximab vedotin, doxorubicin, vinblastine, a
Autor:
Wojciech, Jurczak, Alicja M, Gruszka, Anna, Sowa Staszczak, Monika, Dlugosz-Danecka, Marta, Szostek, Dagmara, Zimowska-Curylo, Agnieszka, Giza, Katarzyna, Krawczyk, Malgorzata, Jakobczyk, Alicja, Hubalewska-Dydejczyk, Michal, Szymczyk, Tomasz, Wróbel, Wanda, Knopińska-Posłuszny, Elżbieta, Kisiel, Aleksander, Skotnicki, Pier Luigi, Zinzani
Publikováno v:
Leukemialymphoma. 60(11)
Polish Lymphoma Research Group performed a phase-II trial to test whether
Autor:
Nancy L. Bartlett, David J. Straus, Monika Dlugosz-Danecka, Sergey Alekseev, Arpad Illes, Ewa Lech-Maranda, Tatyana A. Feldman, Piotr Smolewski, Kerry J Savage, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Munoz, Won-Seog Kim, Ranjana H Advani, Stephen M Ansell, Anas Younes, Andrea Gallamini, Harry Miao, Rachael Liu, Keenan Fenton, Andres Forero-Torres, Marco Picardi
Publikováno v:
Blood. 134:4026-4026
Introduction: As previously reported, the combination of brentuximab vedotin with doxorubicin, vinblastine and dacarbazine (A+AVD) demonstrated a statistically significant improvement in modified progression free survival (modified PFS) compared with
Autor:
Steven Le Gouill, Monika Długosz-Danecka, Simon Rule, Pier Luigi Zinzani, Andre Goy, Stephen D. Smith, Jeanette K. Doorduijn, Carlos Panizo, Bijal D. Shah, Andrew J. Davies, Richard Eek, Eric Jacobsen, Arnon P. Kater, Tadeusz Robak, Preetesh Jain, Roser Calvo, Lin Tao, Michael Wang
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
Externí odkaz:
https://doaj.org/article/c4917574fe414e708d9135d90b9b085d
Autor:
Monika Dlugosz Danecka, Agnieszka Olszanecka, Katarzyna Krawczyk, Aleksander B. Skotnicki, Wojciech Jurczak
Publikováno v:
Journal of Clinical Oncology. 33:e19515-e19515
e19515 Background: Advances in anti-lymphoma therapy and subsequent prolongation of overall survival, make doxorubicin cardiotoxicity an important clinical issue. Methods: Doxorubicin cardiotoxicit...
Autor:
Peter Borchmann, Alexander Fosså, Monika Długosz-Danecka, Boris Böll, Markus Dietlein, Carsten Kobe, Helen Goergen, Andreas Engert
Publikováno v:
HemaSphere, Vol 2, Iss 3 (2018)
Externí odkaz:
https://doaj.org/article/85edf5fba5ed4e7e9bd974972f7a1d07